$7.17
1.26% today
Nasdaq, Sep 19, 05:48 pm CET
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Aurinia Pharmaceuticals Inc. Stock price

$7.08
+0.64 9.94% 1M
+1.99 39.10% 6M
-1.91 21.25% YTD
-1.32 15.71% 1Y
-13.83 66.14% 3Y
+1.16 19.59% 5Y
+3.68 108.24% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
-0.06 0.84%
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Key metrics

Market capitalization $1.01b
Enterprise Value $767.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.71
P/S ratio (TTM) P/S ratio 4.89
P/B ratio (TTM) P/B ratio 2.78
Revenue growth (TTM) Revenue growth 29.35%
Revenue (TTM) Revenue $207.11m
EBIT (operating result TTM) EBIT $-45.64m
Free Cash Flow (TTM) Free Cash Flow $-1.34m
Cash position $330.48m
EPS (TTM) EPS $-0.35
P/E forward 1,416.00
P/S forward 4.37
EV/Sales forward 3.32
Short interest 6.13%
Show more

Is Aurinia Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Aurinia Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

Buy
86%
Hold
14%

Financial data from Aurinia Pharmaceuticals Inc.

Dec '23
+/-
%
Net Profit -78 -78
28% 28%
-44%
Depreciation and Amortization 12 12
330% 330%
7%
Stock Compensation 45 45
40% 40%
26%
Operating Cash Flow -33 -33
58% 58%
-19%
Investments 0.72 0.72
148% 148%
0%
Dividend Paid - -
-
-
Free Cash Flow -34 -34
57% 57%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Aurinia Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aurinia Pharmaceuticals Inc. Stock News

Positive
Seeking Alpha
about 4 hours ago
Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. The partnership with Otsuka Pharmaceutical supports Aurinia's international expansion into European and Asian markets. AUR200, now in Phase 1 trials, could be a significant future value driver targe...
Positive
Seeking Alpha
one day ago
Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales. AUPH is developing AUR200, with a phase 1 trial underway allowing it to diversify beyond Lupkynis. The Company reported a $722K net income for Q2'24, up from a $10.7M net loss in Q1'24.
Neutral
Business Wire
6 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference.
More Aurinia Pharmaceuticals Inc. News

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Head office Canada
CEO Peter Greenleaf
Employees 300
Founded 1993
Website www.auriniapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today